Book Online
Make a Booking

Meningococcal Vaccine Booster Study

Meningococcal Vaccine Booster Study

OVERVIEW

Several different germs can cause a serious infection of the blood and nervous system. A germ (bacterium) called the meningococcus, can cause several serious diseases, including meningitis and infection of the blood. Meningitis affects the brain and spinal cord. It can cause hearing loss, seizures, learning and behaviour problems, severe brain damage and even death (death is caused in about half the cases if left untreated). Meningitis can happen to anyone but is more common in teenagers, and young children (including babies). This research study will help us learn about an experimental new vaccine that might protect against diseases caused by different types of meningococcus germs (types A, B, C, W, Y).

An experimental new vaccine has to be tested and approved by national health agencies before it can be marketed and given to people in the general community. Several studies are done to test an experimental vaccine.. National health agencies look at the results of these studies and then decide whether to approve an experimental vaccine for use. All routine vaccines that you or your child receive have been through this same process.

This study is being conducted to learn more about the safety and immune response of the study vaccine MenABCWY, in healthy adolescents and adults from 15 through 25 years of age when given as a booster 4-6 years after receiving a previous meningitis vaccine (MenACWY).

THE INVESTIGATIONAL VACCINE

The MenABCWY vaccine has been developed based upon two of GSK’s already marketed vaccines, Menveo (MenACWY vaccine) and Bexsero (MenB vaccine). Bexsero is a vaccine that helps to protect against the meningococcus B germ. Menveo is a vaccine that helps protect against types A, C, W and Y of the meningococcus germ. The use of Bexsero and Menveo has been approved in Australia. Bexsero and Menveo are approved for people from 2 months of age.

WHAT HAPPENS?

You will be required to come to our clinic 4 times, each visit you will see the study doctor and then the research team for vaccination or blood draw.

There is no cost for the vaccine or study visits, and you will be compensated for time and travel.

TO BE ELIGIBLE YOU MUST:

PRINCIPAL INVESTIGATOR

A/Prof Mark Bloch

CONTACT US

Please contact Holdsworth House Research to register your interest:

Phone: 02 8038 1044

Email: studies@holdsworthhouse.com.au

Or enter your details here to request more information.

Contact Details